Back to search results

Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

Abroad (travel likely)RecruitingPHASE2

Conditions

Hepatocellular Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

    Contact: Study coordinator (Debra Diecks) · diecksda@upmc.edu · 4126238364
    Contact: Principal Investigator (Anwaar Saeed, MD)

  • Houston Methodist Neal Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Safiya Joseph, RC) · sdjoseph@houstonmethodist.org · 346-238-2420
    Contact: Study coordinator (Frances Saubon, RC) · fsaubon@houstonmethodist.org · (832) 522-8398
    Contact: Principal Investigator (Maen Abdelrahim, MD)

  • Mays Cancer Center, UT Health San Antonio, San Antonio, Texas, United States

    Contact: Study coordinator (Jennifer Moseley) · moseleyj@uthscsa.edu
    Contact: Study coordinator (Ofelia Romero) · romeroo@uthscsa.edu
    Contact: Principal Investigator (Sukeshi Patel Arora, MD)
Study leads

  • Anwaar M Saeed, MD

    Principal Investigator

    UPMC Hillman Cancer Center

View source on ClinicalTrials.gov(opens in a new tab)